Interview 11 Jul 2017 The Advantage for the First Mover in NASH is Limited, says Genfit …mortality as well as cardiovascular events. “The leading cause of mortality is cardiovascular events and disease, not so much liver events,” he noted. But how do you design a preventative… July 11, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2017 Quantum Worms from London win the Biodesign Challenge 2017 …screens and solar panels, and the market is expected to reach $11Bn (€9.6Bn) by 2026. The students present a method developed at King’s College London to produce these quantum dots… July 1, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2025 Kriya Therapeutics has raised over $1.2 billion, but for what? …manufacture of gene therapies at up to 2,000-liter bioreactor scale. Then, about a year later, with no mention of pipeline progress, the biotech revealed that it had bagged $100 million… September 10, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 24 Apr 2024 Overcoming toxicities: are IL-2 smart cytokines the next big thing? …to overcome this, IL-2 superkines, which are essentially engineered cytokines, have been created. Mural Oncology steers the way with nemvaleukin American biotech Mural Oncology leads this space with its drug… April 24, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2021 Next-Generation mRNA Vaccine Technology Unveiled in Series A Round …mRNA vaccines and therapies, which include novel cancer therapies, is expected to grow by almost 30% per year through 2026, when it is expected to reach €2.4B ($2.9B). The comparative… June 1, 2021 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
In Depth 9 Jul 2025 New hope for CIPN: Can emerging therapies ease chemotherapy’s nerve damage? …been initiated in healthy volunteers. The company plans to initiate phase 2 trials in the second half of 2026. In addition to headliners, a Pharma‑Technology overview from 2024 counted 61… July 9, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by Stad Gent 9 Dec 2025 How world-class infrastructure will reinforce Ghent’s position as Europe’s biopharma hub …options for your tech. Bio-Incubator at VIB, a leading institute in life sciences research and innovation Photo credits: VIB If you’re looking to plug into a vast biotech ecosystem, this… December 9, 2025 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Seven pharma companies form alliance to prepare for future pandemics …diseases with pandemic potential ready for phase II/III clinical trials by 2026. As a first step, the INTREPID alliance will publish an initial list of promising antiviral compounds later this… July 20, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Oct 2025 Eight AI deals in 2025: Discover where industry leaders are betting big Artificial intelligence (AI) is rapidly transforming the biotechnology landscape, and as it does, we are seeing more and more strategic collaborations and partnerships focused on the technology. These partnerships make… October 28, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 14 Feb 2024 The next leap in pet health: longevity drugs for dogs …the approval of longevity drugs for dogs? One company pursuing this goal is San Francisco-based biotech startup Loyal. The company currently has three drugs in development and under review with… February 14, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development and commercialization of imeglimin, a new treatment for metabolic disorders like type 2 diabetes…. February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2025 ITM-11 succeeds in phase 3: The first big win for radiopharma? …potent alpha radiation. Their lead candidate targets neuroendocrine tumors and could launch in 2026 following successful clinical trials. As the industry advances, addressing the challenges of isotope supply, manufacturing, and… January 28, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email